Excited to announce Bioxodes will attend #ISC2025 (Feb 5–7)! Valérie Pireaux will present preclinical data on BIOX-101, targeting intracerebral hemorrhage — an unmet need in stroke care. Let’s connect at ISC! 🚀 #StrokeCare #Innovation #Bioxodes #ISC2025

Full house @BrainDays ! Our CMO, Dr. Hans Warrinnier, delivered a high-impact pitch on BIOX-101 at #BrainInnovationDays, highlighting our solution for unmet medical needs. Honored to be selected to pitch & showcase a poster among top innovators! #BIOX101 #strokecare #Bioxodes

Very much looking forward to attending the @BrainDays and to share our innovation through a poster presentation! Let's meet in Brussels and talk about brain health. #voiceofstroke #ICH #strokecare

Some of the most exciting therapies in the future could come from animals @Labiotech_eu Interesting read and thank you for mentioning @bioxodes ! #Biotech #Innovation #Healthcare #LifeSciences #Belgium #ticksaliva #stroke #voiceofstroke

RT @BioWin_asbl: @bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflam…

#BioEquity 2024 is just around the corner! @EBDgroup @BioCentury Our CEO is looking forward to present Bioxodes' progress and vision to potential investors. See you in San Sebastian! #Bioxodes #BioEquity24

Exciting news! Our CEO, Marc Dechamps, will be sharing latest updates on BIOX-101 (Ir-CPI), our groundbreaking therapy for intracerebral hemorrhage on several conferences. #EITSummit #Sachs_ELSF #LSXWorld #BioEquity

Our CEO Marc Dechamps will be presenting at the upcoming #biotechshowcase in #SanFrancisco ! Curious to hear more about our latest developments? See you there! @EBDgroup #JPMorgan

Prepping for #bioeurope, our CEO Marc Dechamps is all set for #partnering! Our mission to advance healthcare solutions for #stroke is stronger than ever! #IrCPI @EBDgroup

Proud to share that our CEO Marc Dechamps, has been awarded with the 'Biotechnology CEO of the Year - Europe' title at the 2023 Business Worldwide Magazine CEO Awards! 🏆 Full PR

🌟 Exciting Update! We presented our groundbreaking research on Ir-CPI at #ISTH2023. Revolutionizing #thrombosis treatment and #neuroinflammation! @isth HealthcareInnovation #Bioxodes

🔻 MEDIA ARTICLE 🔺 Could a bioactive peptide secreted in the saliva of ticks offer a useful therapy for people who have experienced #intracerebral #hemorrhage (#ICH)? Read the interview of our CEO, Marc Dechamps by @BioWorld here👇

@isth

Last week, @bioxodes  was in Munich, Germany, to attend the 9th European Stroke Organization Conference (#ESOC2023). Valérie Pireaux, Preclinical Scientist, presented data on Ir-CPI in a model of intracerebral hemorrhage. You can view the poster here: 🧠 

Part of Bioxodes' team is attending #ESOC2023. 👉 Reach us if you want to know more about our drug candidate Ir-CPI in intracerebral haemorrhage. You can also consult our e-poster on-site

Yesterday our Clinical Project Manager Charlotte Corbisier did a great job presenting at #ESOTA! She explained our approach, as a small biotech company, to a phase IIa trial on Ir-CPI. Stay tuned for more news coming soon! #stroke #strokeprevention #voiceofstroke #ESOC2023

Join us at the #ESOC2023 organised by @ESOstroke! The @bioxodes team will give multiple presentations on our lead candidate #Ir-CPI and the important progress we made since inception! #stroke #brainthrombosis #neuroinflammation

RT @ALA_Group: [ALA Client News] @bioxodes presents latest developments at key international conferences - on first-in-class drug candidate…

PRESS RELEASE Interesting times for @bioxides! Meet us at the following conferences @BioEquity @EBDgroup @isth @esocstroke PR: